全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Renal Prognostic Benefit of High Cut Off Dialysis Membrane Treatment in the Management of Dialysis-Dependent Severe Acute Renal Failure Secondary to Myeloma Cast Nephropathy in a Local Cohort

DOI: 10.4236/oalib.1113463, PP. 1-13

Keywords: End-Stage Renal Disease, Myeloma Tubulopathy, Multiple Myeloma, Hemodialysis, Nephrology, Perpignan

Full-Text   Cite this paper   Add to My Lib

Abstract:

Introduction: The objective of this observational study on a local cohort was to report the prognostic interest of using a High Cut-Off membrane dialysis protocol in the management of MM (myeloma tubulopathy) in patients with severe dialysis-dependent acute kidney injury (AKI). Methodology: This was a retrospective study conducted over a one-year period from September 1, 2023, to August 31, 2024. All hospitalized patients with dialysis-dependent AKI diagnosed with MM were treated according to the High Cut-Off protocol of usual chemotherapy. A free light chain proteinuria level above 1500 mg/L was required to confirm the diagnosis of MM. Results: In our cohort, we included 14 patients diagnosed with MM, 9 of whom were treated with the High Cut-Off protocol. Among these, 5 recovered renal function (RF), and 4 did not; 5 patients underwent conventional dialysis without RF recovery. The average age was 77 years, ranging from 45 to 92 years, with the highest age group being 65 to 85 years. Women were predominant, with a sex ratio of 1.4. The hematological diagnosis was similar in all groups (HCO , HCO-, and conventional dialysis). Our results show a higher percentage of patients with subacute MM or pre-existing chronic kidney disease (CKD) in the HCO group, with mean creatinine levels of 133 μmol/L, 117 μmol/L, and 106.5 μmol/L, respectively. No patient with creatinine > 115 μmol/L was found in the HCO group, while there were 3/5 (60%) in the HCO- group and 5 in the conventional dialysis group. A significant decrease in free light chain levels was observed at the end of the protocol in 4 patients (25%) in the HCO group compared to none (0%) in the conventional dialysis group. In the group treated successfully with the HCO protocol, the time to RF recovery after initiating HCO treatment was 3 months for 3 patients and 6 months for 2 patients. Conclusion: In our study, the results suggest that the HCO protocol is beneficial, with 56% of patients weaned from dialysis, while no recovery was observed in the untreated group. Renal recovery was most notable around the third month after initiating the protocol. Further studies are needed to confirm these findings. This renal recovery, along with dialysis weaning, could have a significant positive impact on the quality of life of patients with MM and beneficial medico-economic repercussions.

References

[1]  Leung, N. and Rajkumar, S.V. (2023) Multiple Myeloma with Acute Light Chain Cast Nephropathy. Blood Cancer Journal, 13, Article No. 46. https://doi.org/10.1038/s41408-023-00806-w
[2]  Faguer, S. and Roussel, M. (2016) Patients with Multiple Myeloma Have Excellent Long-Term Outcomes after Recovery from Dialysis-Dependent Acute Kidney Injury. Eu-ropean Journal of Haematology, 96, 547-548. https://doi.org/10.1111/ejh.12696
[3]  Bladé, J., Fernandez-Llama, P., Bosch, F., et al. (1998) Insuffisance rénale dans le myélome multiple: Présentation des caractéristiques et des facteurs prédictifs de l’évolution chez 94 patients d’un seul établissement. The Archives of Internal Medicine, 158, 1889-1893.
[4]  Knudsen, L.M., Hjorth, M. and Hippe, E. (2000) Insuffisance rénale dans le myélome multiple: Réversibilité et impact sur le pronostic. Groupe d’étude sur le myélome nordique. European Journal of Haematology, 65, 175-181.
[5]  Haynes, R.J., Read, S., Collins, G.P., Darby, S.C. and Winearls, C.G. (2009) Presentation and Survival of Pa-tients with Severe Acute Kidney Injury and Multiple Myeloma: A 20-Year Experience from a Single Centre. Nephrology Di-alysis Transplantation, 25, 419-426. https://doi.org/10.1093/ndt/gfp488
[6]  Kastritis, E., Anagnostopoulos, A., Roussou, M., et al. (2007) Réversibilité de l’insuffisance rénale chez les patients atteints d’un myélome multiple nouvellement diagnostiqué et traités à haute dose schémas thérapeutiques contenant de la dexaméthasone et impact des nouveaux agents. Hématologique, 92, 546-549.
[7]  Dimopoulos, M.A., Roussou, M., Gkotzamanidou, M., et al. (2013) Le rôle du roman agents sur la réversibilité de l’insuffisance rénale chez les patients nouvellement diagnostiqués patients symptomatiques atteints de myélome multiple. Leucémie, 27, 423-429.
[8]  Hutchison, C.A., Cockwell, P., Reid, S., Chan-dler, K., Mead, G.P., Harrison, J., et al. (2007) Efficient Removal of Immunoglobulin Free Light Chains by Hemodialysis for Multiple Myeloma: In Vitro and in Vivo Studies. Journal of the American Society of Nephrology, 18, 886-895. https://doi.org/10.1681/asn.2006080821
[9]  Leung, N., Gertz, M.A., Zeldenrust, S.R., Rajkumar, S.V., Dispenzieri, A., Fervenza, F.C., et al. (2008) Improvement of Cast Nephropathy with Plasma Exchange Depends on the Diagnosis and on Reduction of Serum Free Light Chains. Kidney International, 73, 1282-1288. https://doi.org/10.1038/ki.2008.108
[10]  Ecotière, L., Thierry, A., Debiais-Delpech, C., Chevret, S., Javaugue, V., Desport, E., et al. (2015) Prognostic Value of Kidney Biopsy in Myeloma Cast Nephropathy: A Retrospective Study of 70 Patients. Nephrology Dialysis Transplantation, 31, 64-72. https://doi.org/10.1093/ndt/gfv283
[11]  Colin, A., et al. (2019) High Cutoff versus High-Flux Haemodialysis for Myelomacastnephropathy in Patients Receiving Bortezomib-Based Chemotherapy (EuLITE): A Phase 2 Randomised Controlled Trial. The Lancet Haematology, 6, e217-e228.
[12]  Marion, S., et al. (2019) Myeloma Cast Nephropathy: The Dusk of High Cutoff Haemodialysis. The Lancet Haematology, 6, e174-e176.
[13]  Mikhael, J., Manola, J., Dueck, A.C., Hayman, S., Oettel, K., Kanate, A.S., et al. (2018) Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma and Impaired Renal Function: PrE1003, a PrECOG Study. Blood Cancer Journal, 8, Article No. 86. https://doi.org/10.1038/s41408-018-0110-7

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133